Whole-exome sequencing and adrenocorticotropic hormone therapy in individuals with infantile spasms

Aim To identify additional genes associated with infantile spasms using a cohort with defined infantile spasms. Method Whole-exome sequencing (WES) was performed on 21 consented individuals with infantile spasms and their unaffected parents (a trio-based study). Clinical history and imaging were reviewed. Potentially deleterious exonic variants were identified and segregated. To refine potential candidates, variants were further prioritized on the basis of evidence for relevance to disease phenotype or known associations with infantile spasms, epilepsy, or neurological disease. Results Likely pathogenic de novo variants were identified in NR2F1, GNB1, NEUROD2, GABRA2, and NDUFAF5. Suggestive dominant and recessive candidate variants were identified in PEMT, DYNC1I1, ASXL1, RALGAPB, and STRADA; further confirmation is required to support their relevance to disease etiology. Interpretation This study supports the utility of WES in uncovering the genetic etiology in undiagnosed individuals with infantile spasms with an overall yield of five out of 21. High-priority candidates were identified in an additional five individuals. WES provides additional support for previously described disease-associated genes and expands their already broad mutational and phenotypic spectrum.

Automated summary

This study aimed to identify additional genes associated with infantile spasms using whole-exome sequencing on a cohort of 21 individuals with infantile spasms. Likely pathogenic de novo variants and candidate variants were identified, supporting the utility of WES in uncovering the genetic etiology in undiagnosed individuals with infantile spasms. High-priority candidates were identified, expanding the mutational and phenotypic spectrum of disease-associated genes.